Moody’s downgrades Senegal to Caa1 amid rising debt concerns
McKesson Corporation stock reached an all-time high of $738.51, marking a significant milestone for the $91.4 billion healthcare services and information technology company that generated $377.6 billion in revenue over the past twelve months. According to InvestingPro analysis, the company is currently trading at Fair Value. Over the past year, McKesson’s stock has experienced a robust 53% increase, reflecting strong investor confidence and the company’s consistent performance in the healthcare sector. This surge to an all-time high underscores McKesson’s resilience and strategic growth initiatives, which have been well-received in the market. With an excellent Financial Health Score of 3.08 and notably low price volatility (Beta: 0.51), the company has demonstrated strong fundamentals. InvestingPro subscribers can access 15 additional key insights about McKesson, including detailed analysis of its aggressive share buyback program and 32-year dividend payment history.
In other recent news, McKesson Corporation reported its first-quarter fiscal year 2026 earnings, exceeding Wall Street expectations. The company achieved an earnings per share of $8.26, surpassing the forecasted $8.19, and reported revenue of $97.8 billion, which was higher than the anticipated $95.82 billion. Additionally, McKesson announced a reorganization of its reportable segments, effective in the second quarter of fiscal year 2026, aimed at enhancing strategic alignment and transparency. The new structure will include five segments: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions, and Other, which involves operations in Norway under a definitive sale agreement.
Analysts at Jefferies have lowered their price target for McKesson to $84 from $90, maintaining a Buy rating, citing tariff and geopolitical pressures. Meanwhile, UBS reduced its price target to $79 from $83, keeping a Neutral rating, and noted McKesson’s capital allocation strategy as a solid use of capital. Despite these developments, McKesson’s management has maintained its fiscal year guidance. These changes and assessments reflect the ongoing strategic adjustments and market evaluations impacting McKesson.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.